In a note on Monday downgrading their rating of Humana to "Hold" from "Buy", the TD Cowen analysts flagged ... Analysts at ...
The company will continue to invest in brands and supply-chain capabilities as it targets $1 billion in sales by 2027.
VANCOUVER, British Columbia and SAN FRANCISCO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), a biotechnology company focused on developing best-in-class therapies for ...
In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Waters (WAT – Research Report), with a price target of ...
Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand ...
VANCOUVER, British Columbia and SAN FRANCISCO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), a biotechnology company focused on developing best-in-class therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results